{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:50:46Z","timestamp":1791388246214,"version":"4.3.3"},"reference-count":207,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Program for Basic Research in the Russian Federation for a long-term period (2021-2030)","award":["122030100170-5"],"award-info":[{"award-number":["122030100170-5"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Monoamine oxidase inhibitors are widely used for the symptomatic treatment of Parkinson\u2019s disease (PD). They demonstrate antiparkinsonian activity in different toxin-based models induced by 6-hydroxydopamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and pesticides (rotenone and paraquat). In some models, such as MPTP-induced PD, MAO inhibitors prevent the formation of the neurotoxin MPP+ from the protoxin MPTP. Regardless of the toxin\u2019s nature, potent MAO inhibitors prevent dopamine loss reduction, the formation of hydrogen peroxide, hydrogen peroxide signaling, and the accumulation of hydrogen peroxide-derived reactive oxygen species responsible for the development of oxidative stress. It becomes increasingly clear that some metabolites of MAO inhibitors (e.g., the rasagiline metabolite 1-R-aminoindan) possess their own bio-pharmacological activities unrelated to the parent compound. In addition, various MAO inhibitors exhibit multitarget action, in which MAO-independent effects prevail. This opens new prospects in the development of novel therapeutics based on simultaneous actions on several prospective targets for the therapy of PD.<\/jats:p>","DOI":"10.3390\/ijms26031248","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T06:42:36Z","timestamp":1738305756000},"page":"1248","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism"],"prefix":"10.3390","volume":"26","author":[{"given":"Olga","family":"Buneeva","sequence":"first","affiliation":[{"name":"Institute of Biomedical Chemistry, 10 Pogodinskaya Street, 119121 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Medvedev","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, 10 Pogodinskaya Street, 119121 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The Epidemiology of Parkinson\u2019s Disease","volume":"403","author":"Darweesh","year":"2024","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12264-022-00934-6","article-title":"Parkinson\u2019s Disease: A Multisystem Disorder","volume":"39","author":"Costa","year":"2022","journal-title":"Neurosci. Bull."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson\u2019s Disease: Mechanisms and Models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, Regional, and National Burden of Neurological Disorders, 1990\u20132016: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_5","unstructured":"Stoker, T.B., and Greenland, J.C. (2018). Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects, Codon Publications."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and Treatment of Parkinson Disease: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100163","DOI":"10.1016\/j.dscb.2024.100163","article-title":"Novel Approaches Targeting \u03b1-Synuclein for Parkinson\u2019s Disease: Current Progress and Future Directions for the Disease-Modifying Therapies","volume":"16","author":"Baggett","year":"2024","journal-title":"Brain Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The Pathogenesis of Parkinson\u2019s Disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41531-021-00203-9","article-title":"Alpha-Synuclein Research: Defining Strategic Moves in the Battle against Parkinson\u2019s Disease","volume":"7","author":"Oliveira","year":"2021","journal-title":"NPJ Park. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson Disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/jnc.14810","article-title":"The Physiological Role of \u03b1-Synuclein and Its Relationship to Parkinson\u2019s Disease","volume":"150","author":"Sulzer","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/mds.26605","article-title":"Neuropathological Basis of Nonmotor Manifestations of Parkinson\u2019s Disease","volume":"31","author":"Adler","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/mds.26510","article-title":"Nonmotor Features of Parkinson\u2019s Disease Subtypes","volume":"31","author":"Marras","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","article-title":"Genetics and Pathogenesis of Parkinson\u2019s Syndrome","volume":"18","author":"Ye","year":"2023","journal-title":"Annu. Rev. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5483\/BMBRep.2019.52.4.204","article-title":"Disease Model Organism for Parkinson Disease: Drosophila Melanogaster","volume":"52","author":"Aryal","year":"2019","journal-title":"BMB Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrn.2017.75","article-title":"Animal Models of \u03b1-Synucleinopathy for Parkinson Disease Drug Development","volume":"18","author":"Koprich","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/15548627.2018.1509818","article-title":"Mitochondrial Dysfunction and Mitophagy Defect Triggered by Heterozygous GBA Mutations","volume":"15","author":"Li","year":"2019","journal-title":"Autophagy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1871527320666210809120621","article-title":"Drosophila: A Model to Study the Pathogenesis of Parkinson\u2019s Disease","volume":"21","author":"Rahul","year":"2022","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ramonet, D., Daher, J.P.L., Lin, B.M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., and Yang, L. (2011). Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018568"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-211-45295-0_40","article-title":"Limitations of Cellular Models in Parkinson\u2019s Disease Research","volume":"Volume 70","author":"Riederer","year":"2006","journal-title":"Parkinson\u2019s Disease and Related Disorders"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.31083\/j.jin2201020","article-title":"SH-SY5Y Cell Line In Vitro Models for Parkinson Disease Research-Old Practice for New Trends","volume":"22","author":"Ioghen","year":"2023","journal-title":"J. Integr. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ejn.14345","article-title":"Induced Pluripotent Stem Cell-Based Modeling of Mutant LRRK2-Associated Parkinson\u2019s Disease","volume":"49","author":"Weykopf","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In Vivo Demonstration That Alpha-Synuclein Oligomers Are Toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.14336\/AD.2020.0331","article-title":"Comprehensive Perspectives on Experimental Models for Parkinson\u2019s Disease","volume":"12","author":"Ke","year":"2021","journal-title":"Aging Dis."},{"key":"ref_25","unstructured":"Stoker, T.B., and Greenland, J.C. (2018). Animal Models of Parkinson\u2019s Disease. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects, Codon Publications."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"NS20210026","DOI":"10.1042\/NS20210026","article-title":"Animal Models of Parkinson\u2019s Disease: A Guide to Selecting the Optimal Model for Your Research","volume":"5","author":"Lama","year":"2021","journal-title":"Neuronal Signal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1759091418777438","DOI":"10.1177\/1759091418777438","article-title":"Neurotoxin-Induced Animal Models of Parkinson Disease: Pathogenic Mechanism and Assessment","volume":"10","author":"Zeng","year":"2018","journal-title":"ASN Neuro"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Blesa, J., Phani, S., Jackson-Lewis, V., and Przedborski, S. (2012). Classic and New Animal Models of Parkinson\u2019s Disease. J. Biomed. Biotechnol., 2012.","DOI":"10.1155\/2012\/845618"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Khan, E., Hasan, I., and Haque, M.E. (2023). Parkinson\u2019s Disease: Exploring Different Animal Model Systems. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24109088"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00702-023-02730-6","article-title":"Toxic Interactions between Dopamine, \u03b1-Synuclein, Monoamine Oxidase, and Genes in Mitochondria of Parkinson\u2019s Disease","volume":"131","author":"Naoi","year":"2024","journal-title":"J. Neural Transm."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yeung, A.W.K., Georgieva, M.G., Atanasov, A.G., and Tzvetkov, N.T. (2019). Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis. Front. Mol. Neurosci., 12.","DOI":"10.3389\/fnmol.2019.00143"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The Therapeutic Potential of Monoamine Oxidase Inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.neuro.22.1.197","article-title":"Monoamine Oxidase: From Genes to Behavior","volume":"22","author":"Shih","year":"1999","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00702-010-0562-9","article-title":"Transcriptional Regulation and Multiple Functions of MAO Genes","volume":"118","author":"Shih","year":"2011","journal-title":"J. Neural Transm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","article-title":"Update on the Pharmacology of Selective Inhibitors of MAO-A and MAO-B: Focus on Modulation of CNS Monoamine Neurotransmitter Release","volume":"143","author":"Finberg","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00702-018-1927-8","article-title":"Monoamine oxidase isoenzymes: Genes, functions and targets for behavior and cancer therapy","volume":"125","author":"Shih","year":"2018","journal-title":"J. Neural Transm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0306-4522(88)90250-3","article-title":"Localization of Distinct Monoamine Oxidase A and Monoamine Oxidase B Cell Populations in Human Brainstem","volume":"25","author":"Westlund","year":"1988","journal-title":"Neuroscience"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Finberg, J.P.M., and Rabey, J.M. (2016). Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Front. Pharmacol., 7.","DOI":"10.3389\/fphar.2016.00340"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2174\/156802612805219950","article-title":"Type A and B Monoamine Oxidase in Age-Related Neurodegenerative Disorders: Their Distinct Roles in Neuronal Death and Survival","volume":"12","author":"Naoi","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s42269-023-01018-9","article-title":"Design of New Reversible and Selective Inhibitors of Monoamine Oxidase A and a Comparison with Drugs Already Approved","volume":"47","year":"2023","journal-title":"Bull. Natl. Res. Cent."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1586\/ern.09.68","article-title":"Functional Mechanism of Neuroprotection by Inhibitors of Type B Monoamine Oxidase in Parkinson\u2019s Disease","volume":"9","author":"Naoi","year":"2009","journal-title":"Expert. Rev. Neurother."},{"key":"ref_42","first-page":"7479","article-title":"Monoamine Oxidase-B Inhibition Facilitates \u03b1-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson\u2019s Disease","volume":"41","author":"Nakamura","year":"2021","journal-title":"J. Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1673-5374.375299","article-title":"Type-B Monoamine Oxidase Inhibitors in Neurological Diseases: Clinical Applications Based on Preclinical Findings","volume":"19","author":"Alborghetti","year":"2024","journal-title":"Neural Regen. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543776.2018.1427735","article-title":"MAO Inhibitors and Their Wider Applications: A Patent Review","volume":"28","author":"Carradori","year":"2018","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00702-018-1942-9","article-title":"Monoamine Oxidase Inhibitors, and Iron Chelators in Depressive Illness and Neurodegenerative Diseases","volume":"125","author":"Youdim","year":"2018","journal-title":"J. Neural Transm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.parkreldis.2008.04.015","article-title":"The 6-Hydroxydopamine Model: News from the Past","volume":"14","author":"Blandini","year":"2008","journal-title":"Park. Relat. Disord."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF03033565","article-title":"The 6-Hydroxydopamine Model of Parkinson\u2019s Disease","volume":"11","author":"Simola","year":"2007","journal-title":"Neurotox. Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Chotibut, T., Apple, D.M., Jefferis, R., and Salvatore, M.F. (2012). Dopamine Transporter Loss in 6-OHDA Parkinson\u2019s Model Is Unmet by Parallel Reduction in Dopamine Uptake. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0052322"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00702-004-0203-2","article-title":"Dopamine Transporter: Involvement in Selective Dopaminergic Neurotoxicity and Degeneration","volume":"111","author":"Storch","year":"2004","journal-title":"J. Neural Transm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00702-019-02133-6","article-title":"6-Hydroxydopamine: A Far from Simple Neurotoxin","volume":"127","author":"Tipton","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_51","first-page":"329","article-title":"Inhibition of Mitochondrial Complexes I and IV by 6-Hydroxydopamine","volume":"292","author":"Glinka","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"ref_52","first-page":"533","article-title":"The 6-Hydroxydopamine Model and Parkinsonian Pathophysiology: Novel Findings in an Older Model","volume":"32","year":"2017","journal-title":"Neurolog\u00eda"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Pantic, I., Cumic, J., Skodric, S.R., Dugalic, S., and Brodski, C. (2021). Oxidopamine and Oxidative Stress: Recent Advances in Experimental Physiology and Pharmacology. Chem.-Biol. Interact., 336.","DOI":"10.1016\/j.cbi.2021.109380"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00441-004-0938-y","article-title":"Classic Toxin-Induced Animal Models of Parkinson\u2019s Disease: 6-OHDA and MPTP","volume":"318","author":"Schober","year":"2004","journal-title":"Cell Tissue Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/bi992296v","article-title":"Interaction between 6-Hydroxydopamine and Transferrin:\u2009 \u201cLet My Iron Go\u201d","volume":"39","author":"Borisenko","year":"2000","journal-title":"Biochemistry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1039\/b408044k","article-title":"New Insights into Iron Release from Ferritin: Direct Observation of the Neurotoxin 6-Hydroxydopamine Entering Ferritin and Reaching Redox Equilibrium with the Iron Core","volume":"2","author":"Jameson","year":"2004","journal-title":"Org. Biomol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.bcp.2004.02.015","article-title":"Dopamine toxicity involves mitochondrial complex I inhibition: Implications to dopamine-related neuropsychiatric disorders","volume":"67","author":"Zuk","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1074\/jbc.M511560200","article-title":"6-Hydroxydopamine-Induced Apoptosis Is Mediated via Extracellular Auto-Oxidation and Caspase 3-Dependent Activation of Protein Kinase C\u03b4","volume":"281","author":"Hanrott","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.freeradbiomed.2006.12.004","article-title":"Molecular Mechanisms of 6-Hydroxydopamine-Induced Cytotoxicity in PC12 Cells: Involvement of Hydrogen Peroxide-Dependent and -Independent Action","volume":"42","author":"Saito","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"153281","DOI":"10.1016\/j.phymed.2020.153281","article-title":"Theacrine, a Purine Alkaloid from Kucha, Protects against Parkinson\u2019s Disease through SIRT3 Activation","volume":"77","author":"Duan","year":"2020","journal-title":"Phytomedicine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s11033-020-05284-y","article-title":"Protective Effects of Cinnamomum Verum, Cinnamomum Cassia and Cinnamaldehyde against 6-OHDA-Induced Apoptosis in PC12 Cells","volume":"47","author":"Ramazani","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Tai, S., Zheng, Q., Zhai, S., Cai, T., Xu, L., Yang, L., Jiao, L., and Zhang, C. (2020). Alpha-Lipoic Acid Mediates Clearance of Iron Accumulation by Regulating Iron Metabolism in a Parkinson\u2019s Disease Model Induced by 6-OHDA. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.00612"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"423","DOI":"10.31083\/j.jin.2019.04.192","article-title":"Baicalin Attenuated Substantia Nigra Neuronal Apoptosis in Parkinson\u2019s Disease Rats via the mTOR\/AKT\/GSK-3\u03b2 Pathway","volume":"18","author":"Zhai","year":"2019","journal-title":"JIN"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0378-4274(02)00013-9","article-title":"Interactions of the Neurotoxin 6-Hydroxydopamine with Glyceraldehyde-3-Phosphate Dehydrogenase","volume":"128","author":"Hayes","year":"2002","journal-title":"Toxicol. Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s41467-018-03538-9","article-title":"A Comprehensive Map Coupling Histone Modifications with Gene Regulation in Adult Dopaminergic and Serotonergic Neurons","volume":"9","author":"Toskas","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1021\/pr100389u","article-title":"Differential Proteome of the Striatum from Hemiparkinsonian Rats Displays Vivid Structural Remodeling Processes","volume":"9","author":"Lessner","year":"2010","journal-title":"J. Proteome Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuint.2010.04.005","article-title":"Proteomic Analysis of Expression and Protein Interactions in a 6-Hydroxydopamine-Induced Rat Brain Lesion Model","volume":"57","author":"Park","year":"2010","journal-title":"Neurochem. Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/BF00978370","article-title":"The Determination of Hydroxydopamines and Other Trace Amines in the Urine of Parkinsonian Patients and Normal Controls","volume":"18","author":"Andrew","year":"1993","journal-title":"Neurochem. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0021-9673(00)90882-3","article-title":"Mass Fragmentography of Dopamine and 6-Hydroxydopamine. Application to the Determination of Dopamine in Human Brain Biopsies from the Caudate Nucleus","volume":"99","author":"Curtius","year":"1974","journal-title":"J. Chromatogr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.neuint.2009.11.008","article-title":"L-DOPA-Induced 6-Hydroxydopamine Production in the Striata of Rodents Is Sensitive to the Degree of Denervation","volume":"56","author":"Borah","year":"2010","journal-title":"Neurochem. Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5214\/ans.0972.7531.2009.160406","article-title":"Long Term L-DOPA Treatment Causes Production of 6-OHDA in the Mouse Striatum: Involvement of Hydroxyl Radical","volume":"16","author":"Borah","year":"2010","journal-title":"Ann. Neurosci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00702-023-02692-9","article-title":"L-DOPA-Therapy in Parkinson\u2019s Disease: Some Personal Reflections on L-DOPA Therapy from Vienna and Berlin","volume":"130","author":"Riederer","year":"2023","journal-title":"J. Neural Transm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1046\/j.1471-4159.1995.65031213.x","article-title":"Influence of Selective Inhibition of Monoamine Oxidase A or B on Striatal Metabolism of L-DOPA in Hemiparkinsonian Rats","volume":"65","author":"Finberg","year":"1995","journal-title":"J. Neurochem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bph.12349","article-title":"Increased L-DOPA-Derived Dopamine Following Selective MAO-A or -B Inhibition in Rat Striatum Depleted of Dopaminergic and Serotonergic Innervation","volume":"170","author":"Loboda","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1046\/j.1471-4159.1994.63010108.x","article-title":"L-3,4-Dihydroxyphenylalanine-Induced Dopamine Release in the Striatum of Intact and 6-Hydroxydopamine-Treated Rats: Differential Effects of Monoamine Oxidase A and B Inhibitors","volume":"63","author":"Wachtel","year":"1994","journal-title":"J. Neurochem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-3565(25)28637-2","article-title":"Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons","volume":"174","author":"Breese","year":"1970","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/archneur.1975.00490440064010","article-title":"Brain Peroxidase and Catalase in Parkinson Disease","volume":"32","author":"Ambani","year":"1975","journal-title":"Arch. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s11064-008-9610-3","article-title":"Free Copper, Ferroxidase and SOD1 Activities, Lipid Peroxidation and NO(x) Content in the CSF. A Different Marker Profile in Four Neurodegenerative Diseases","volume":"33","author":"Boll","year":"2008","journal-title":"Neurochem. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/sj.bjp.0706019","article-title":"Locomotor Effects of Imidazoline I2-Site-Specific Ligands and Monoamine Oxidase Inhibitors in Rats with a Unilateral 6-Hydroxydopamine Lesion of the Nigrostriatal Pathway","volume":"143","author":"MacInnes","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s004010050453","article-title":"Monoamine Oxidase B Inhibitor Selegiline Protects Young and Aged Rat Peripheral Sympathetic Neurons against 6-Hydroxydopamine-Induced Neurotoxicity","volume":"91","author":"Salonen","year":"1996","journal-title":"Acta Neuropathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.bbr.2018.03.002","article-title":"Selegiline Increases on Time without Exacerbation of Dyskinesia in 6-Hydroxydopamine-Lesioned Rats Displaying l-Dopa-Induced Wearing-off and Abnormal Involuntary Movements","volume":"347","author":"Tsunekawa","year":"2018","journal-title":"Behav. Brain Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/exnr.1994.1204","article-title":"Chronic Treatment with Levodopa and\/or Selegiline Does Not Affect Behavioral Recovery Induced by Fetal Ventral Mesencephalic Grafts in Unilaterally 6-Hydroxydopamine-Lesioned Rats","volume":"130","author":"Adams","year":"1994","journal-title":"Exp. Neurol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuropharm.2012.08.023","article-title":"Selective Inhibition of Monoamine Oxidase A or B Reduces Striatal Oxidative Stress in Rats with Partial Depletion of the Nigro-Striatal Dopaminergic Pathway","volume":"65","author":"Aluf","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuroscience.2017.10.018","article-title":"Neuroprotective and Neuro-Restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson\u2019s Disease","volume":"367","author":"Cronin","year":"2017","journal-title":"Neuroscience"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.expneurol.2004.03.005","article-title":"Neuroprotective Effect of Rasagiline in a Rodent Model of Parkinson\u2019s Disease","volume":"187","author":"Blandini","year":"2004","journal-title":"Exp. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.brainres.2015.11.028","article-title":"BDNF Levels Are Increased by Aminoindan and Rasagiline in a Double Lesion Model of Parkinson\u2019s Disease","volume":"1631","author":"Ledreux","year":"2016","journal-title":"Brain Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1471-4159.2007.04777.x","article-title":"Aminoindan and Hydroxyaminoindan, Metabolites of Rasagiline and Ladostigil, Respectively, Exert Neuroprotective Properties in Vitro","volume":"103","author":"Amit","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/138945012799499794","article-title":"Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimer\u2019s Disease Treatment","volume":"13","author":"Weinreb","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00702-009-0225-x","article-title":"Genomic and Proteomic Study to Survey the Mechanism of Action of the Anti-Parkinson\u2019s Disease Drug, Rasagiline Compared with Selegiline, in the Rat Midbrain","volume":"116","author":"Weinreb","year":"2009","journal-title":"J. Neural Transm."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/ars.2010.3282","article-title":"Does 1-(R)-Aminoindan Possess Neuroprotective Properties against Experimental Parkinson\u2019s Disease?","volume":"14","author":"Weinreb","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1046\/j.0953-816x.2001.01563.x","article-title":"Protective Effect of Harmaline and Harmalol against Dopamine- and 6-Hydroxydopamine-Induced Oxidative Damage of Brain Mitochondria and Synaptosomes, and Viability Loss of PC12 Cells","volume":"13","author":"Kim","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Kadnikov, I.A., Verbovaya, E.R., Voronkov, D.N., Voronin, M.V., and Seredenin, S.B. (2020). Deferred Administration of Afobazole Induces Sigma1R-Dependent Restoration of Striatal Dopamine Content in a Mouse Model of Parkinson\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207620"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Voronin, M.V., Kadnikov, I.A., Voronkov, D.N., and Seredenin, S.B. (2019). Chaperone Sigma1R Mediates the Neuroprotective Action of Afobazole in the 6-OHDA Model of Parkinson\u2019s Disease. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-53413-w"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0304-3940(02)00614-6","article-title":"Neuroprotective Effect of the Monoamine Oxidase Inhibitor PF 9601N [N-(2-Propynyl)-2-(5-Benzyloxy-Indolyl) Methylamine] on Rat Nigral Neurons after 6-Hydroxydopamine-Striatal Lesion","volume":"329","author":"Cutillas","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/jpet.118.251645","article-title":"Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia","volume":"367","author":"Gardoni","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/nan.12263","article-title":"Neuroprotection by Safinamide in the 6-Hydroxydopamine Model of Parkinson\u2019s Disease","volume":"42","author":"Sadeghian","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"108024","DOI":"10.1016\/j.neuropharm.2020.108024","article-title":"Effects of Safinamide on the Glutamatergic Striatal Network in Experimental Parkinson\u2019s Disease","volume":"170","author":"Sciaccaluga","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1021\/jm501722s","article-title":"Novel Arylalkenylpropargylamines as Neuroprotective, Potent, and Selective Monoamine Oxidase B Inhibitors for the Treatment of Parkinson\u2019s Disease","volume":"58","author":"Huleatt","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.neurobiolaging.2014.10.026","article-title":"Neuroprotective and Neurorestorative Activities of a Novel Iron Chelator-Brain Selective Monoamine Oxidase-A\/Monoamine Oxidase-B Inhibitor in Animal Models of Parkinson\u2019s Disease and Aging","volume":"36","author":"Amit","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neulet.2003.10.067","article-title":"Contrasting Neuroprotective and Neurotoxic Actions of Respective Metabolites of Anti-Parkinson Drugs Rasagiline and Selegiline","volume":"355","author":"Amit","year":"2004","journal-title":"Neurosci. Lett."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10517-009-0630-z","article-title":"Effect of Afobazole on Mitochondrial Monoamine Oxidase A Activity in Vitro","volume":"148","author":"Voronin","year":"2009","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.fct.2011.04.026","article-title":"Inhibition of the Bioactivation of the Neurotoxin MPTP by Antioxidants, Redox Agents and Monoamine Oxidase Inhibitors","volume":"49","author":"Herraiz","year":"2011","journal-title":"Food Chem. Toxicol."},{"key":"ref_104","first-page":"S11","article-title":"The MPTP Story","volume":"7","author":"Langston","year":"2017","journal-title":"J. Park. Dis."},{"key":"ref_105","first-page":"19","article-title":"MPTP Mouse Models of Parkinson\u2019s Disease: An Update","volume":"1","author":"Meredith","year":"2011","journal-title":"J. Park. Dis."},{"key":"ref_106","first-page":"422","article-title":"MPTP-Induced Mouse Model of Parkinson\u2019s Disease: A Promising Direction for Therapeutic Strategies","volume":"21","author":"Mustapha","year":"2021","journal-title":"Bosn. J. Basic. Med. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molbrainres.2004.09.017","article-title":"The MPTP model of Parkinson\u2019s disease","volume":"134","author":"Smeyne","year":"2005","journal-title":"Mol. Brain Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0167-4889(98)00071-8","article-title":"MPP+ Toxicity and Plasma Membrane Dopamine Transporter: Study Using Cell Lines Expressing the Wild-Type and Mutant Rat Dopamine Transporters","volume":"1404","author":"Kitayama","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s007020100004","article-title":"Neurochemical Findings in the MPTP Model of Parkinson\u2019s Disease","volume":"108","author":"Schmidt","year":"2001","journal-title":"J. Neural Transm."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/mgg3.469","article-title":"miR-34a\/BCL-2 Signaling Axis Contributes to Apoptosis in MPP+ -Induced SH-SY5Y Cells","volume":"6","author":"Shanesazzade","year":"2018","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1471-4159.2001.00096.x","article-title":"Dopaminergic Cell Death Induced by MPP(+), Oxidant and Specific Neurotoxicants Shares the Common Molecular Mechanism","volume":"76","author":"Chun","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.18632\/oncotarget.14650","article-title":"Oxidative Stress in Neurodegenerative Disease: Causation or Association?","volume":"8","author":"Vega","year":"2017","journal-title":"Oncotarget"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"8038","DOI":"10.1007\/s12035-018-0950-y","article-title":"Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: An Inside in the Pathology of Parkinson\u2019s Disease","volume":"55","author":"Niranjan","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-017-1788-5","article-title":"Parkinson\u2019s Disease: Experimental Models and Reality","volume":"135","author":"Jiang","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40478-020-0894-0","article-title":"Early-Onset Impairment of the Ubiquitin-Proteasome System in Dopaminergic Neurons Caused by \u03b1-Synuclein","volume":"8","author":"McKinnon","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e98878","DOI":"10.15252\/embj.201798878","article-title":"\u03b1-Synuclein Stimulation of Monoamine oxidase-B and Legumain Protease Mediates the Pathology of Parkinson\u2019s Disease","volume":"37","author":"Kang","year":"2018","journal-title":"EMBO J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"51","DOI":"10.18097\/pbmc20216701051","article-title":"Changes in the mitochondrial subproteome of mouse brain Rpn13-binding proteins induced by the neurotoxin MPTP and the neuroprotector isatin","volume":"67","author":"Buneeva","year":"2021","journal-title":"Biomed. Khim"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1134\/S0006297919110117","article-title":"Ubiquitin Subproteome of Brain Mitochondria and Its Changes Induced by Experimental Parkinsonism and Action of Neuroprotectors","volume":"84","author":"Buneeva","year":"2019","journal-title":"Biochem. Mosc."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"316","DOI":"10.18097\/PBMC20176304316","article-title":"The effect of neurotoxin MPTP administration to mice on the proteomic profile of brain isatin-binding proteins","volume":"63","author":"Buneeva","year":"2017","journal-title":"Biomed. Khim"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/pr070546l","article-title":"Mitochondrial Dysfunction, Oxidative Stress, and Apoptosis Revealed by Proteomic and Transcriptomic Analyses of the Striata in Two Mouse Models of Parkinson\u2019s Disease","volume":"7","author":"Chin","year":"2008","journal-title":"J. Proteome Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.molbrainres.2004.10.003","article-title":"Quantitative Proteomic Analysis of Mitochondrial Proteins: Relevance to Lewy Body Formation and Parkinson\u2019s Disease","volume":"134","author":"Jin","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bbrc.2008.08.142","article-title":"Striatal 19S Rpt6 Deficit Is Related to Alpha-Synuclein Accumulation in MPTP-Treated Mice","volume":"376","author":"Liu","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1021\/pr901024z","article-title":"Region-Specific Protein Abundance Changes in the Brain of MPTP-Induced Parkinson\u2019s Disease Mouse Model","volume":"9","author":"Zhang","year":"2010","journal-title":"J. Proteome Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1021\/pr101211k","article-title":"Alterations in the Mitochondrial Proteome of Neuroblastoma Cells in Response to Complex 1 Inhibition","volume":"10","author":"Hargreaves","year":"2011","journal-title":"J. Proteome Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1007\/s12035-017-0559-6","article-title":"MPTP Mouse Model of Preclinical and Clinical Parkinson\u2019s Disease as an Instrument for Translational Medicine","volume":"55","author":"Mingazov","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neuroscience.2011.03.007","article-title":"Modeling of Presymptomatic and Symptomatic Stages of Parkinsonism in Mice","volume":"181","author":"Ugrumov","year":"2011","journal-title":"Neuroscience"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.6332378","article-title":"Pargyline Prevents MPTP-Induced Parkinsonism in Primates","volume":"225","author":"Langston","year":"1984","journal-title":"Science"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0014-2999(93)90897-Q","article-title":"L-Deprenyl Confers Specific Protection against MPTP-Induced Parkinson\u2019s Disease-like Movement Disorder in the Goldfish","volume":"240","author":"Adeyemo","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1749-6632.1996.tb39078.x","article-title":"Suppression of Hydroxyl Radical Formation and Protection of Nigral Neurons by L-Deprenyl (Selegiline)","volume":"786","author":"Wu","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1124\/mol.105.012302","article-title":"Role of the Redox Protein Thioredoxin in Cytoprotective Mechanism Evoked by (-)-Deprenyl","volume":"68","author":"Andoh","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/311467a0","article-title":"Protection against the Dopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine by Monoamine Oxidase Inhibitors","volume":"311","author":"Heikkila","year":"1984","journal-title":"Nature"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s007020170018","article-title":"Monoamine Oxidase-Inhibition and MPTP-Induced Neurotoxicity in the Non-Human Primate: Comparison of Rasagiline (TVP 1012) with Selegiline","volume":"108","author":"Kupsch","year":"2001","journal-title":"J. Neural Transm."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13024-015-0067-y","article-title":"Novel (Hetero)Arylalkenyl Propargylamine Compounds Are Protective in Toxin-Induced Models of Parkinson\u2019s Disease","volume":"11","author":"Baranyi","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.bjp.0703826","article-title":"Rasagiline [N-Propargyl-1R(+)-Aminoindan], a Selective and Potent Inhibitor of Mitochondrial Monoamine Oxidase B","volume":"132","author":"Youdim","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1007\/s11064-007-9351-8","article-title":"Rasagiline Promotes Regeneration of Substantia Nigra Dopaminergic Neurons in Post-MPTP-Induced Parkinsonism via Activation of Tyrosine Kinase Receptor Signaling Pathway","volume":"32","author":"Mandel","year":"2007","journal-title":"Neurochem. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.nbd.2006.07.020","article-title":"Activation of Tyrosine Kinase Receptor Signaling Pathway by Rasagiline Facilitates Neurorescue and Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP-Induced Parkinsonism","volume":"25","author":"Sagi","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12640-009-9070-9","article-title":"Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30","volume":"17","author":"Gal","year":"2010","journal-title":"Neurotox. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/S1353-8020(11)70047-5","article-title":"M30, a Brain Permeable Multitarget Neurorestorative Drug in Post Nigrostriatal Dopamine Neuron Lesion of Parkinsonism Animal Models","volume":"18","author":"Youdim","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s12031-017-0891-3","article-title":"Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson\u2019s Disease Model","volume":"61","author":"Liu","year":"2017","journal-title":"J. Mol. Neurosci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.pnpbp.2008.03.004","article-title":"The Effect of Lamotrigine on Platelet Monoamine Oxidase Type B Activity in Patients with Bipolar Depression","volume":"32","author":"Sagud","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1203\/PDR.0b013e31806790d7","article-title":"Lamotrigine Is Neuroprotective in the Energy Deficiency Model of MPTP Intoxicated Mice","volume":"62","author":"Lagrue","year":"2007","journal-title":"Pediatr. Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1471-4159.2000.0750521.x","article-title":"Protective Effect of Harmalol and Harmaline on MPTP Neurotoxicity in the Mouse and Dopamine-Induced Damage of Brain Mitochondria and PC12 Cells","volume":"75","author":"Lee","year":"2000","journal-title":"J. Neurochem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0168-0102(03)00097-X","article-title":"N-Methylated Beta-Carbolines Protect PC12 Cells from Cytotoxic Effect of MPP+ by Attenuation of Mitochondrial Membrane Permeability Change","volume":"46","author":"Park","year":"2003","journal-title":"Neurosci. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10787-007-1614-0","article-title":"Inhibition of Monoamine Oxidase-B by the Polyphenolic Compound, Curcumin and Its Metabolite Tetrahydrocurcumin, in a Model of Parkinson\u2019s Disease Induced by MPTP Neurodegeneration in Mice","volume":"16","author":"Rajeswari","year":"2008","journal-title":"Inflammopharmacology"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Buneeva, O., Kopylov, A., Kapitsa, I., Ivanova, E., and Medvedev, A. (2020, January 30). Neuroprotective mechanisms of action of endogenous regulator isatin in MPTP induced Parkinsonism. Proceedings of the Neuroscience for Medicine and Psychology.","DOI":"10.29003\/m971.sudak.ns2020-16\/120-121"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Buneeva, O., Kopylov, A., Kapitsa, I., Ivanova, E., Zgoda, V., and Medvedev, A. (2018). The Effect of Neurotoxin MPTP and Neuroprotector Isatin on the Profile of Ubiquitinated Brain Mitochondrial Proteins. Cells, 7.","DOI":"10.3390\/cells7080091"},{"key":"ref_147","first-page":"330","article-title":"Brain Mitochondrial Subproteome of Rpn10-Binding Proteins and Its Changes Induced by the Neurotoxin MPTP and the Neuroprotector Isatin","volume":"82","author":"Medvedev","year":"2017","journal-title":"Biochemistry"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1023\/A:1026119708124","article-title":"Antioxidant Effect of Phenelzine on MPP+-Induced Cell Viability Loss in Differentiated PC12 Cells","volume":"28","author":"Lee","year":"2003","journal-title":"Neurochem. Res."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Bhattamisra, S.K., Yap, K.H., Rao, V., and Choudhury, H. (2019). Multiple Biological Effects of an Iridoid Glucoside, Catalpol, and Its Underlying Molecular Mechanisms. Biomolecules, 10.","DOI":"10.3390\/biom10010032"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neuroscience.2010.01.048","article-title":"Catalpol Attenuates MPTP Induced Neuronal Degeneration of Nigral-Striatal Dopaminergic Pathway in Mice through Elevating Glial Cell Derived Neurotrophic Factor in Striatum","volume":"167","author":"Xu","year":"2010","journal-title":"Neuroscience"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.tiv.2008.09.007","article-title":"Catalpol Protects Mesencephalic Neurons against MPTP Induced Neurotoxicity via Attenuation of Mitochondrial Dysfunction and MAO-B Activity","volume":"22","author":"Bi","year":"2008","journal-title":"Toxicol. Vitr."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejphar.2007.04.039","article-title":"Neuroprotective Effect of Catalpol against MPP(+)-Induced Oxidative Stress in Mesencephalic Neurons","volume":"568","author":"Tian","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Medvedev, A., Kopylov, A., Buneeva, O., Kurbatov, L., Tikhonova, O., Ivanov, A., and Zgoda, V. (2020). A Neuroprotective Dose of Isatin Causes Multilevel Changes Involving the Brain Proteome: Prospects for Further Research. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21114187"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/pmic.200900492","article-title":"Isatin-Binding Proteins of Rat and Mouse Brain: Proteomic Identification and Optical Biosensor Validation","volume":"10","author":"Buneeva","year":"2010","journal-title":"Proteomics"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/biof.1408","article-title":"Isatin, an Endogenous Nonpeptide Biofactor: A Review of Its Molecular Targets, Mechanisms of Actions, and Their Biomedical Implications","volume":"44","author":"Medvedev","year":"2018","journal-title":"BioFactors"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12035-012-8291-8","article-title":"Rodent Models and Contemporary Molecular Techniques: Notable Feats yet Incomplete Explanations of Parkinson\u2019s Disease Pathogenesis","volume":"46","author":"Yadav","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s12640-021-00356-8","article-title":"Neurotoxin-Induced Rodent Models of Parkinson\u2019s Disease: Benefits and Drawbacks","volume":"39","author":"Salama","year":"2021","journal-title":"Neurotox. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s12035-022-03193-8","article-title":"Rotenone-Induced Model of Parkinson\u2019s Disease: Beyond Mitochondrial Complex I Inhibition","volume":"60","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-1-0716-1495-2_10","article-title":"Generation of Mitochondrial Toxin Rodent Models of Parkinson\u2019s Disease Using 6-OHDA, MPTP, and Rotenone","volume":"2322","author":"Maegawa","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3109\/10408444.2012.680431","article-title":"Mitochondrial Complex I Inhibitor Rotenone-Induced Toxicity and Its Potential Mechanisms in Parkinson\u2019s Disease Models","volume":"42","author":"Xiong","year":"2012","journal-title":"Crit. Rev. Toxicol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.12.003","article-title":"Intersecting Pathways to Neurodegeneration in Parkinson\u2019s Disease: Effects of the Pesticide Rotenone on DJ-1, \u03b1-Synuclein, and the Ubiquitin\u2013Proteasome System","volume":"22","author":"Betarbet","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S1353-8020(03)00023-3","article-title":"The Rotenone Model of Parkinson\u2019s Disease: Genes, Environment and Mitochondria","volume":"9","author":"Greenamyre","year":"2003","journal-title":"Park. Relat. Disord."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/exnr.2002.8072","article-title":"Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and Alpha-Synuclein Aggregation","volume":"179","author":"Sherer","year":"2003","journal-title":"Exp. Neurol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2174\/0113894501281496231226070459","article-title":"Effect of Rotenone on the Neurodegeneration among Different Models","volume":"25","author":"Subhan","year":"2024","journal-title":"Curr. Drug Targets"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Elmorsy, E., Al-Ghafari, A., Al Doghaither, H., Hashish, S., Salama, M., Mudyanselage, A.W., James, L., and Carter, W.G. (2023). Differential Effects of Paraquat, Rotenone, and MPTP on Cellular Bioenergetics of Undifferentiated and Differentiated Human Neuroblastoma Cells. Brain Sci., 13.","DOI":"10.3390\/brainsci13121717"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5114\/fn.2019.89857","article-title":"Rotenone: From Modelling to Implication in Parkinson\u2019s Disease","volume":"57","author":"Radad","year":"2019","journal-title":"Folia Neuropathol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.freeradbiomed.2013.01.003","article-title":"Oxidative Damage to Macromolecules in Human Parkinson Disease and the Rotenone Model","volume":"62","author":"Sanders","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"188","DOI":"10.18097\/pbmc20236903188","article-title":"Quantitative Changes of Brain Isatin-Binding Proteins of Rats with the Rotenone-Induced Experimental Parkinsonism","volume":"69","author":"Buneeva","year":"2023","journal-title":"Biomed. Khim"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1021\/pr500894v","article-title":"Metabolome and Proteome Profiling of Complex I Deficiency Induced by Rotenone","volume":"14","author":"Gielisch","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Jin, J., Davis, J., Zhu, D., Kashima, D.T., Leroueil, M., Pan, C., Montine, K.S., and Zhang, J. (2007). Identification of Novel Proteins Affected by Rotenone in Mitochondria of Dopaminergic Cells. BMC Neurosci., 8.","DOI":"10.1186\/1471-2202-8-67"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"39155","DOI":"10.1074\/jbc.M405456200","article-title":"Analysis of \u03b1-Synuclein-Associated Proteins by Quantitative Proteomics*[Boxs]","volume":"279","author":"Zhou","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"25","DOI":"10.18097\/pbmc20247001025","article-title":"The Delayed Effect of Rotenone on the Relative Content of Brain Isatin-Binding Proteins of Rats with Experimental Parkinsonism","volume":"70","author":"Buneeva","year":"2024","journal-title":"Biomed. Khim"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0006-8993(01)02577-X","article-title":"Carrier-Mediated Processes in Blood\u2013Brain Barrier Penetration and Neural Uptake of Paraquat","volume":"906","author":"Shimizu","year":"2001","journal-title":"Brain Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13024-016-0135-y","article-title":"Role of Cytochrome c in \u03b1-Synuclein Radical Formation: Implications of \u03b1-Synuclein in Neuronal Death in Maneb- and Paraquat-Induced Model of Parkinson\u2019s Disease","volume":"11","author":"Kumar","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Jagmag, S.A., Tripathi, N., Shukla, S.D., Maiti, S., and Khurana, S. (2015). Evaluation of Models of Parkinson\u2019s Disease. Front. Neurosci., 9.","DOI":"10.3389\/fnins.2015.00503"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1007\/s12035-022-02799-2","article-title":"Cellular and Molecular Events Leading to Paraquat-Induced Apoptosis: Mechanistic Insights into Parkinson\u2019s Disease Pathophysiology","volume":"59","author":"See","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.parkreldis.2023.105932","article-title":"Paraquat (Herbicide) as a Cause of Parkinson\u2019s Disease","volume":"119","author":"Sharma","year":"2024","journal-title":"Park. Relat. Disord."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/labinvest.2015.161","article-title":"Multifactorial Theory Applied to the Neurotoxicity of Paraquat and Paraquat-Induced Mechanisms of Developing Parkinson\u2019s Disease","volume":"96","author":"Zhang","year":"2016","journal-title":"Lab. Investig."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bbadis.2013.03.019","article-title":"Minocycline, Levodopa and MnTMPyP Induced Changes in the Mitochondrial Proteome Profile of MPTP and Maneb and Paraquat Mice Models of Parkinson\u2019s Disease","volume":"1832","author":"Dixit","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Mol. Basis Dis."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ntt.2007.04.002","article-title":"Identification of Differentially Expressed Proteins in Striatum of Maneb-and Paraquat-Induced Parkinson\u2019s Disease Phenotype in Mouse","volume":"29","author":"Patel","year":"2007","journal-title":"Neurotoxicol Teratol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuint.2005.12.016","article-title":"L-Deprenyl Protects against Rotenone-Induced, Oxidative Stress-Mediated Dopaminergic Neurodegeneration in Rats","volume":"49","author":"Saravanan","year":"2006","journal-title":"Neurochem. Int."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/01616412.2017.1297911","article-title":"Effects of Eldepryl on Glial Cell Proliferation and Activation in the Substantia Nigra and Striatum in a Rat Model of Parkinson\u2019s Disease","volume":"39","author":"Liu","year":"2017","journal-title":"Neurol. Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.brainres.2015.08.033","article-title":"Autophagy-Related Protein Expression in the Substantia Nigra and Eldepryl Intervention in Rat Models of Parkinson\u2019s Disease","volume":"1625","author":"Liu","year":"2015","journal-title":"Brain Res."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/taap.2001.9130","article-title":"Attenuation of Paraquat-Induced Dopaminergic Toxicity on the Substantia Nigra by (\u2212)-Deprenyl in Vivo","volume":"172","author":"Liou","year":"2001","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.neuint.2010.06.017","article-title":"Rasagiline Protects against Alpha-Synuclein Induced Sensitivity to Oxidative Stress in Dopaminergic Cells","volume":"57","author":"Chau","year":"2010","journal-title":"Neurochem. Int."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"290","DOI":"10.18097\/pbmc20236905290","article-title":"Neuroprotective Effects of Isatin and Afobazole in Rats with Rotenone-Induced Parkinsonism Are Accompanied by Increased Brain Levels of Triton X-100 Soluble Alpha-Synuclein","volume":"69","author":"Buneeva","year":"2023","journal-title":"Biomed. Khim"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"231","DOI":"10.18097\/pbmc20247004231","article-title":"The Neuroprotective Effect of Isatin in the Rotenone-Induced Model of Parkinonism in Rats: The Study of Delayed Effects","volume":"70","author":"Buneeva","year":"2024","journal-title":"Biomed. Khim."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1096\/fj.13-235481","article-title":"Monoamine Oxidase-A Knockdown in Human Neuroblastoma Cells Reveals Protection against Mitochondrial Toxins","volume":"28","author":"Fitzgerald","year":"2014","journal-title":"FASEB J."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejphar.2013.03.015","article-title":"Strain Differences in Profiles of Dopaminergic Neurotransmission in the Prefrontal Cortex of the BALB\/C vs. C57Bl\/6 Mice: Consequences of Stress and Afobazole","volume":"708","author":"Anderzhanova","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00702-020-02150-w","article-title":"Rasagiline and Selegiline Modulate Mitochondrial Homeostasis, Intervene Apoptosis System and Mitigate \u03b1-Synuclein Cytotoxicity in Disease-Modifying Therapy for Parkinson\u2019s Disease","volume":"127","author":"Naoi","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0304-3940(00)01439-7","article-title":"The Stimulating Effects of Ethanol Consumption on Synthesis of Rat Brain Monoamine Oxidases and Their Sensitivity to the Irreversible Inhibitor, Pargyline","volume":"292","author":"Panova","year":"2000","journal-title":"Neurosci. Lett."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.1471-4159.2003.01564.x","article-title":"In Situ Imaging of Specific Binding of [3H]Isatin in Rat Brain","volume":"84","author":"Medvedev","year":"2003","journal-title":"J. Neurochem."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-8993(02)03187-6","article-title":"Effects of Short- and Long-Term (\u2212)-Deprenyl Administration on mRNA for Copper, Zinc- and Manganese-Superoxide Dismutase and Glutathione Peroxidase in Rat Brain","volume":"953","author":"Kunikowska","year":"2002","journal-title":"Brain Res."},{"key":"ref_194","first-page":"BR269","article-title":"The Effect of Short-Term Administration of (-)-Deprenyl and Isatin on the Expressions of Some Genes in the Mouse Brain Cortex","volume":"14","author":"Fedchenko","year":"2008","journal-title":"Med. Sci. Monit."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(90)90139-W","article-title":"Clorgyline Displays High Affinity for Sigma Binding Sites in C57BL\/6 Mouse Brain","volume":"176","author":"Itzhak","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0304-3940(02)00332-4","article-title":"An Anti-Parkinson\u2019s Disease Drug, N-Propargyl-1(R)-Aminoindan (Rasagiline), Enhances Expression of Anti-Apoptotic Bcl-2 in Human Dopaminergic SH-SY5Y Cells","volume":"326","author":"Akao","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1096\/fj.05-3794fje","article-title":"Regulation of Bcl-2 Family Proteins, Neurotrophic Factors, and APP Processing in the Neurorescue Activity of Propargylamine","volume":"19","author":"Weinreb","year":"2005","journal-title":"FASEB J."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1096\/fj.04-1916fje","article-title":"Neuroprotection via Pro-Survival Protein Kinase C Isoforms Associated with Bcl-2 Family Members","volume":"18","author":"Weinreb","year":"2004","journal-title":"FASEB J."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00702-017-1832-6","article-title":"Type A and B Monoamine Oxidases Distinctly Modulate Signal Transduction Pathway and Gene Expression to Regulate Brain Function and Survival of Neurons","volume":"125","author":"Naoi","year":"2018","journal-title":"J. Neural Transm."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/mutage\/gem016","article-title":"Antioxidant Properties of Beta-Carboline Alkaloids Are Related to Their Antimutagenic and Antigenotoxic Activities","volume":"22","author":"Moura","year":"2007","journal-title":"Mutagenesis"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Buneeva, O., and Medvedev, A. (2022). Atypical Ubiquitination and Parkinson\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073705"},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Buneeva, O.A., and Medvedev, A.E. (2016). Atypical Ubiquitination of Proteins. Biomeditsinskaia Khimiia, 62.","DOI":"10.18097\/PBMC20166205496"},{"key":"ref_203","first-page":"1326","article-title":"Effect of Affinity Sorbent on Proteomic Profiling of Isatin-Binding Proteins of Mouse Brain","volume":"77","author":"Buneeva","year":"2012","journal-title":"Biochemistry"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1472-8206.2008.00616.x","article-title":"The Lipopolysaccharide Parkinson\u2019s Disease Animal Model: Mechanistic Studies and Drug Discovery","volume":"22","author":"Dutta","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Kang, S., Noh, Y., Oh, S.J., Yoon, H.J., Im, S., Kwon, H.T., and Pak, Y.K. (2023). Neuroprotective Effects of Aldehyde-Reducing Composition in an LPS-Induced Neuroinflammation Model of Parkinson\u2019s Disease. Molecules, 28.","DOI":"10.3390\/molecules28247988"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Ostadkarampour, M., and Putnins, E.E. (2021). Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.676239"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"4784268","DOI":"10.1155\/2018\/4784268","article-title":"Linking Neuroinflammation and Neurodegeneration in Parkinson\u2019s Disease","volume":"2018","author":"Gelders","year":"2018","journal-title":"J. Immunol. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1248\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:24:52Z","timestamp":1760027092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":207,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26031248"],"URL":"https:\/\/doi.org\/10.3390\/ijms26031248","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]}}}